DRD2

Dopamine receptor D2

Score: 0.694 Price: $0.69 High Druggability Status: active Wiki: DRD2

🧠 Neurodegeneration

HYPOTHESES

PAPERS

KG EDGES

200

DEBATES

3D Protein Structure

🧬 DRD2 — PDB 6CM4 Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

Druggability & Clinical Context

Druggability

High

Score: 0.90

Clinical Stage

Approved

Target Class

Gpcr

Safety

0.60

Druggability Analysis

Drug Development1.00

Structural Tractability0.85

Target Class0.85

Safety Profile0.60

Key Metrics

PDB Structures:

Known Drugs:

Approved:

In Clinical Trials:

Drug Pipeline (14 compounds)

14 Approved

Therapeutic Areas:

CNS/Neuroscience Cardiovascular Pain Neurodegeneration

Druggability Rationale: DRD2 represents a high-druggability target with extensive structural characterization and multiple clinically approved small molecule modulators, indicating robust pharmaceutical tractability. The availability of high-resolution structural data (best resolution 2.19Å) and multiple existing antagonists/agonists like haloperidol and risperidone provide a strong foundation for targeted neurodegeneration drug discovery. The extensive clinical trial history and known pharmacological profiles suggest that DRD2-targeted interventions could be strategically valuable for neurodegenerative conditions with dopaminergic dysregulation.

Mechanism: Small molecule agonist or antagonist modulating dopamine signaling

Drug Pipeline (14 compounds)

14 Approved

Known Drugs:

haloperidol (approved) — schizophrenia, Parkinson's disease

risperidone (approved) — schizophrenia, bipolar disorder

pramipexole (approved) — Parkinson's disease

ropinirole (approved) — Parkinson's disease

CHEMBL2359670 (approved)

CHEMBL3989478 (approved)

CHEMBL1200951 (approved)

CHEMBL567 (approved)

Structural Data:

PDB (10) ✓AlphaFold ✓Cryo-EM ✓

6CM4 6LUQ 6VMS 7DFP 7JVR+5 more

UniProt: F8VUV1

Binding Pocket Analysis:

7TM binding cavity, extracellular loops

🧬 3D Protein Structure

🧬 DRD2 — PDB 6CM4 Click to expand interactive 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll

Selectivity & Safety Considerations

GPCR selectivity should be assessed against related receptor subtypes. Off-target GPCR activity (especially at hERG, muscarinic, and adrenergic receptors) is a common source of clinical adverse effects.